Michael E. Thase, MD

Michael E. Thase, MD, of the University of Pennsylvania

Articles by Michael E. Thase, MD

Maintenance Dosing, Safety Shape GH001 Outlook, With Michael E. Thase, MD

April 3rd 2026

In part 3 of an interview, Michael E. Thase, MD, discusses retreatment timing, safety monitoring, and research priorities following phase 2b GH001 data.

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

ByMichael E. Thase, MD

April 2nd 2026

An interview with Thase explores rapid antidepressant effects and real-world considerations for single-day individualized GH001 dosing in TRD.

Single-Day GH001 Produces Rapid Remission in TRD, With Michael E. Thase, MD

ByMichael E. Thase, MD

March 31st 2026

Inhaled GH001 achieved 57.5% remission by day 8 in TRD with a large effect size vs placebo; Thase discusses interpretation, unblinding, and phase 3 implications.

Lumateperone Shows Broad Symptom Benefit for MDD, With Michael E. Thase, MD

ByMichael E. Thase, MD

January 21st 2026

Adjunctive lumateperone 42 mg improves remission, relieves anxiety and sleep symptoms, and shows sustained safety in patients with treatment-resistant MDD.